Chmp 1A is a mediator of the anti-proliferative effects of All-trans Retinoic Acid in human pancreatic cancer cells

被引:27
|
作者
Li, Jing [1 ]
Orr, Brandon [1 ]
White, Kayla [1 ]
Belogortseva, Natalia [1 ]
Niles, Richard [1 ]
Boskovic, Goran
Nguyen, Hanh [1 ]
Dykes, Ava
Park, Maiyon [1 ]
机构
[1] Marshall Univ, Joan C Edwards Sch Med, Dept Biochem & Microbiol, Huntington, WV 25755 USA
来源
MOLECULAR CANCER | 2009年 / 8卷
关键词
IN-VITRO; BREAST-CANCER; CELLULAR RETINOL-BINDING-PROTEIN-1; PROTEIN EXPRESSION; FAMILIAL SYNDROME; BINDING PROTEINS; P53; DIFFERENTIATION; APOPTOSIS; CARCINOMA;
D O I
10.1186/1476-4598-8-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: We recently have shown that Charged multivesicular protein/Chromatin modifying protein1A (Chmp1A) functions as a tumor suppressor in human pancreatic tumor cells. Pancreatic cancer has the worst prognosis of all cancers with a dismal 5-year survival rate. Preclinical studies using ATRA for treating human pancreatic cancer suggest this compound might be useful for treatment of pancreatic cancer patients. However, the molecular mechanism by which ATRA inhibits growth of pancreatic cancer cells is not clear. The objective of our study was to investigate whether Chmp1A is involved in ATRA-mediated growth inhibition of human pancreatic tumor cells. Results: We performed microarray studies using HEK 293T cells and discovered that Chmp1A positively regulated Cellular retinol-binding protein 1 (CRBP-1). CRBP-1 is a key regulator of All-trans retinoic acid ( ATRA) through ATRA metabolism and nuclear localization. Since our microarray data indicates a potential involvement of Chmp1A in ATRA signaling, we tested this hypothesis by treating pancreatic tumor cells with ATRA in vitro. In the ATRA-responsive cell lines, ATRA significantly increased the protein expression of Chmp1A, CRBP-1, P53 and phospho-P53 at serine 15 and 37 position. We found that knockdown of Chmp1A via shRNA abolished the ATRA-mediated growth inhibition of PanC-1 cells. Also, Chmp1A silencing diminished the increase of Chmp1A, P53 and phospho-P53 protein expression induced by ATRA. In the ATRA non-responsive cells, ATRA did not have any effect on the protein level of Chmp1A and P53. Chmp1A over-expression, however, induced growth inhibition of ATRA non-responsive cells, which was accompanied by an increase of Chmp1A, P53 and phospho-P53. Interestingly, in ATRA responsive cells Chmp1A is localized to the nucleus, which became robust upon ATRA treatment. In the ATRA-non-responsive cells, Chmp1A was mainly translocated to the plasma membrane upon ATRA treatment. Conclusion: Collectively our data provides evidence that Chmp1A mediates the growth inhibitory activity of ATRA in human pancreatic cancer cells via regulation of CRBP-1. Our results also suggest that nuclear localization of Chmp1A is important in mediating ATRA signaling.
引用
收藏
页数:13
相关论文
共 50 条
  • [11] Anti-proliferative and Apoptotic Effects of Valproic Acid on HeLa Cells
    Hashemi, Nasser
    Zoshk, Mojtaba Yousefi
    Rashidian, Amir
    Laripour, Reza
    Fasihi, Hossein
    Hami, Zahra
    Chamanara, Mohsen
    INTERNATIONAL JOURNAL OF CANCER MANAGEMENT, 2022, 15 (05)
  • [12] All-trans retinoic acid influences viability, migration and adhesion of U251 glioblastoma cells
    Vicentic, Jelena Marjanovic
    Schwirtlich, Marija
    Kovacevic-Grujicic, Natasa
    Stevanovic, Milena
    Drakulic, Danijela
    ARCHIVES OF BIOLOGICAL SCIENCES, 2017, 69 (04) : 699 - 706
  • [13] Effect of all-trans retinoic acid on the barrier function in human retinal pigment epithelial cells
    Rong, Junbo
    Liu, Shuangzhen
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2011, 407 (03) : 605 - 609
  • [14] THE EFFECTS OF ALL-TRANS RETINOIC ACID ON BLOOD CELLS IN RAT'S EMBRYO
    Yousefi, Behpour
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 22 (01) : 23 - 26
  • [15] Combined dandelion extract and all-trans retinoic acid induces cytotoxicity in human breast cancer cells
    Rezaie, Hamed
    Alipanah-Moghadam, Reza
    Jeddi, Farhad
    Clark, Cain C. T.
    Aghamohammadi, Vahideh
    Nemati, Ali
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [16] The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid
    Steinmetz, Birgit
    Hackl, Hubert
    Slabakova, Eva
    Schwarzinger, Ilse
    Smejova, Monika
    Spittler, Andreas
    Arbesu, Itziar
    Shehata, Medhat
    Soucek, Karel
    Wieser, Rotraud
    CELL CYCLE, 2014, 13 (18) : 2931 - 2943
  • [17] ERβ1 Sensitizes and ERβ2 Desensitizes ERα-Positive Breast Cancer Cells to the Inhibitory Effects of Tamoxifen, Fulvestrant and Their Combination with All-Trans Retinoic Acid
    Meligova, Aggeliki K.
    Siakouli, Dimitra
    Stasinopoulou, Sotiria
    Xenopoulou, Despoina S.
    Zoumpouli, Maria
    Ganou, Vassiliki
    Gkotsi, Eleni-Fani
    Chatziioannou, Aristotelis
    Papadodima, Olga
    Pilalis, Eleftherios
    Alexis, Michael N.
    Mitsiou, Dimitra J.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (04)
  • [18] The combination of the antiestrogen endoxifen with all-trans-retinoic acid has anti-proliferative and anti-migration effects on melanoma cells without inducing significant toxicity in non-neoplasic cells
    Ribeiro, Mariana P. C.
    Silva, Filomena S. G.
    Paixao, Joana
    Santos, Armanda E.
    Custodio, Jose B. A.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2013, 715 (1-3) : 354 - 362
  • [19] All-trans retinoic acid induces apoptosis in acute myeloblastic leukaemia cells
    A. Zheng
    E.-R. Savolainen
    P. Koistinen
    Apoptosis, 1997, 2 : 319 - 329
  • [20] Anti-tumor activity of all-trans retinoic acid in gastric-cancer: gene-networks and molecular mechanisms
    Guarrera, Luca
    Kurosaki, Mami
    Garattini, Silvio-Ken
    Gianni', Maurizio
    Fasola, Gianpiero
    Rossit, Luca
    Prisciandaro, Michele
    Di Bartolomeo, Maria
    Bolis, Marco
    Rizzo, Paola
    Nastasi, Claudia
    Foglia, Marika
    Zanetti, Adriana
    Paroni, Gabriela
    Terao, Mineko
    Garattini, Enrico
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2023, 42 (01)